Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany

Clinical Drug Investigation

Volumn 24, Issue 8, 2004, Pages 449-455

  Koch, H ^a,b   Landen, H ^b   Stauch, K ^b  

^a Kreiskrankenhaus Beeskow ^*  (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFUROXIME; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; TETRACYCLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NEUROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT;

EID: 4344674592     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424080-00003     Document Type: Article

References (37)

1. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003; 123: 1684-92
2. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003; 97 Suppl. C: 3-14
3. Doll H, Grey-Amante P, Duprat-Lomon I, et al. Quality of life in acute exacerbations of chronic bronchitis: results from a German population study. Respir Med 2002; 96: 39-51
4. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22
5. 1 decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-64
6. Sethi S, Muscarella K, Evans N, et al. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118: 1557-65
7. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-22
8. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117 (5 Suppl. 2): 380-5
9. Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-71
10. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
11. Grossman R. The value of antibiotics and the outcomes of antibiotic therapy in exacerbation of COPD. Chest 1998; 113 (4 Suppl.): 249-55
12. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273: 957-60
13. Adams SG, Anzueto A. Antibiotic therapy in acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15: 234-47
14. Destache CJ. Optimizing economic outcomes in acute exacerbations of chronic bronchitis. Pharmacotherapy 2002; 22 (1 Pt 2): 12-7
15. Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone, 2000: 706-710
16. Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antibiotic Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl. 2: 81-93
17. Liñares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med 1999; 341: 1546-8
18. Morrissey I, Colclough A, Viljoen L, et al. The comparative in vitro activity of moxifloxacin against respiratory tract pathogens isolated during 2003 from LIBRA Targeted Surveillance. Clin Microbiol Infect 2004; 10 Suppl. 3: 117-8
19. Blondeau J, Zhao X, Hansen G, et al. Mutant prevention concentrations (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimocrob Agents Chemother 2001; 45: 433-8
20. Jones ME, Sahm DF, Martin N, et al. Prevalence of gyrA, gyrB, parC and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother 2000; 44: 462-6
21. Jones ME, Karlowsky JA, Blosser-Middleton R, et al. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. Int J Antimicrob Agents 2002; 19: 119-23
22. Li X, Zhao X, Drlica K. Selection of Streptococcus pneumoniae having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob Agents Chemother 2002; 46: 522-4
23. Saravolatz L, Manzor O, Check C, et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 875-7
24. Ackermann G, Schaumann R, Pless B, et al. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: 228-32
25. Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999; 44: 835-8
26. Lister PD, Sanders CC. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 811-8
27. Lode H, Garau J. Improving care for patients with respiratory tract infections. J Chemother 2002; 14 Suppl. 2: 22-8
28. Lorenz J, Busch W, Thate-Waschke I-M, et al. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. J Int Med Res 2001; 29: 61-73
29. Lorenz J, Thate-Waschke I-M, Mast O, et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001; 29: 74-86
30. Miravitlles M, Zalacain R, Murio C, et al. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: results of a two-year study. Clin Drug Invest 2003; 23 (7): 439-50
31. DeAbate CA, Mathew CP, Warner JH, et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir Med 2000; 94: 1029-37
32. Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface 2001; 14: 52-9
33. Bauer T, Landen H. Rapid resolution of symptoms with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis: comparison with prior macrolide treatment. Clin Drug Invest 2002; 22: 641-51
34. Barth J, Landen H. Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis. Clin Drug Invest 2003; 23: 1-10
35. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-13
36. Wilson R, Allegra L, Huchon G, et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-64. In press
37. Lode H, Kubin R, Reiter C. Safety update of oral moxifloxacin: a review of worldwide post-marketing surveillance [abstract]. Clin Microbiol Infect 2002; 8 Suppl. 1: 323-4